Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2018-12-13 Director's Dealing
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2018-12-13 English
PRIMARY DOCUMENT
Director's Dealing
2018-12-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 10, 2018. It announces a press release regarding the results of a Phase 2 clinical trial. The document is short (3299 characters) and primarily serves as a disclosure of a press release rather than containing detailed financial data or comprehensive report content. It does not contain financial statements or substantive financial analysis. The document explicitly states that the press release is attached as an exhibit and is incorporated by reference. This fits the pattern of a Regulatory Filing (RNS) as it is a general regulatory announcement and disclosure rather than a full financial report or earnings release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-12-10 English
8-K
Legal Proceedings Report Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 13, 2018, reporting a legal event: the filing of a securities class action complaint against the company and certain executives. The content focuses on legal proceedings and the company's response to the lawsuit. There are no financial statements, earnings data, or management discussion of financial results. The document is not an annual or quarterly report, nor is it a presentation or voting announcement. It clearly fits the category of Legal Proceedings Report, which covers updates on significant lawsuits and regulatory actions involving the company.
2018-11-13 English
10-Q
Interim / Quarterly Report Q3 2018
2018-11-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 7, 2018, reporting the issuance of a press release announcing financial results for the quarter ended September 30, 2018. The text explicitly states that the press release is being furnished as an exhibit and does not contain the financial results itself, only a notification of their release. The document length is short (2856 characters), and it serves as a current report to announce the earnings release rather than the earnings data itself. According to the rules, such a document is best classified as an Earnings Release (ER) since it announces quarterly financial results, but given it is a Form 8-K furnishing a press release announcing results, it fits the Earnings Release category rather than a full Interim Report or Annual Report. Confidence is high due to clear identification of the document type and content.
2018-11-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.